This inventor holds 89 USPTO granted patents and 8 published patent applications and 7 EPO patents, primarily in Pharmaceutical Inhibitors (CPC class C07D-). Top assignees: Amgen Inc., Wyeth, Ligand Pharmaceuticals, Inc.. Active years: 1997-2025.
Inventors with similar research interests:
Location History:
- Thousands Oaks, CA (US) (2002)
- San Diego, CA (US) (1997 - 2004)
- Thousand Oaks, CA (US) (2001 - 2022)
- Daly City, CA (US) (2021 - 2024)
- San Carlos, CA (US) (2023 - 2024)
Company Filing History:
25 out of 2,069 
16 out of 1,309 
15 out of 139 
Years Active: 1997-2025
Areas of Expertise:
Title: Christopher Michael Tegley: A Maverick Inventor Making Strides in Medical Innovations
Introduction:
Christopher Michael Tegley, a Thousand Oaks-based inventor, is making significant contributions to the field of medical innovations with his impressive portfolio of patents. With over 84 patents to his name, Tegley's groundbreaking research has focused on developing novel treatments for various cancer types and neurological disorders. In this article, we will delve into Tegley's latest patents, highlight his career achievements, explore his collaborations with prominent figures, and appreciate his remarkable contributions to the world of innovations.
Latest Patents:
Tegley's recent patents demonstrate his commitment to revolutionizing cancer treatments and advancing neurology. One notable patent is the development of KRAS G12C inhibitors, which hold great promise for combating pancreatic, colorectal, and lung cancers. These inhibitors, along with their compositions and methods of use, offer new avenues for targeted therapies in the fight against these devastating diseases. Another significant patent focuses on substituted pyridine derivatives as SARM1 inhibitors, which show potential for treating and preventing various neurological disorders.
Career Highlights:
Throughout his career, Tegley has displayed remarkable ingenuity, leading to numerous breakthroughs in medical innovations. With a deep passion for research and an inherent drive for excellence, he has consistently pushed the boundaries of what is possible in the field. Tegley's 84 patents serve as a testament to his relentless pursuit of finding solutions to unmet medical needs and improving patient outcomes.
Collaborations:
Tegley's collaborative efforts have enhanced his ability to tackle complex challenges and bring his ideas to fruition. Two significant figures who have worked alongside Tegley are Lin Zhi and Todd Kevin Jones. Their combined expertise and shared vision have resulted in cross-disciplinary breakthroughs, fostering a vibrant environment for innovation and discovery. By leveraging the diverse skill sets of his collaborators, Tegley has forged new paths towards transforming healthcare.
Conclusion:
Christopher Michael Tegley's extensive patent portfolio reflects his unwavering commitment to innovative advancements in medical science. Through his pioneering research on KRAS G12C inhibitors and SARM1 inhibitors, he has opened doors to potential treatments for cancer and neurological disorders. Tegley's collaborations with notable experts have further accelerated the pace of his groundbreaking work, allowing him to explore fresh perspectives and create impactful solutions. As we look to the future, Tegley's contributions are sure to pave the way for transformative breakthroughs in the field of medical innovations.